Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy

Diabetes and Vascular Disease Research

Volumn 14, Issue 3, 2017, Pages 258-261

  Takenaka, Tsuneo ^a   Kishimoto, Miyako ^a   Ohta, Mari ^a   Tomonaga, Osamu ^b   Suzuki, Hiromichi ^c  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b Tomonaga Clinic   (Japan)

^c Tokyo Musashino Hospital   (Japan)

Author keywords

Albuminuria; proximal tubule; renin angiotensin system; sodium retention; tubuloglomerular feedback

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C; LUSEOGLIFLOZIN; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; SORBITOL;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTIMATED GLOMERULAR FILTRATION RATE; EVENING BLOOD PRESSURE; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORNING BLOOD PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; SCREENING TEST; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; COMPLICATION; DIABETIC NEPHROPATHY; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; KIDNEY; MEDICAL RECORD; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME;

ALBUMINURIA; BIOMARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CANAGLIFLOZIN; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MEDICAL RECORDS; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL; TIME FACTORS; TREATMENT OUTCOME;

EID: 85019017221     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164117690299     Document Type: Article

References (12)

1. Imai Y, Kario K, Shimada K, et al.; Japanese Society of Hypertension Committee for Guidelines for Self-monitoring of Blood Pressure at Home. The Japanese society of hypertension guidelines for self-monitoring of blood pressure at home. (second edition). Hypertens Res 2012; 35: 777-795.
2. Takenaka T, Sato T, Hoshi H, et al. Zigzagged augmentation index in diabetes. Clin Exp Hypertens 2009; 31: 657-668.
3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128.
4. Imai Y, Obara T, Asamaya K, et al. The reason why home blood pressure measurements are preferred over clinic or ambulatory blood pressure in Japan. Hypertens Res 2013; 36: 661-672.
5. Takenaka T, Harrison-Bernard LM, Inscho EW, et al. Autoregulation of afferent arteriolar blood flow in juxtamedullary nephrons. Am J Physiol 1994; 267: F879-F887.
6. Thomson SC, Deng A, Bao D, et al. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 2001; 107: 217-224.
7. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334.
8. Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 2016; 59: 1860-1870.
9. Takenaka T, Inoue T, Okada H, et al. Altered gap junctional communication and renal haemodynamics in Zucker fatty rat model of type 2 diabetes. Diabetologia 2011; 54: 2192-2201.
10. Takenaka T, Inoue T, Ohno Y, et al. Elucidating mechanisms underlying altered renal autoregulation in diabetes. Am J Physiol Regul Integr Comp Physiol 2012; 303: R495-R504.
11. Mori H, Okada Y, Kawaguchi M, et al. A case of type 2 diabetes with a change from a non-dipper to a dipper blood pressure pattern by Dapagliflozin. J UOEH 2016; 38: 149-153.
12. Scheen AJ,. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf 2015; 14: 1879-1904.